CU23149A3 - PROCESO PARA LA PURIFICACION DE PROTEINAS FARMACOLOGICAMENTE ACTIVAS A TRAVéS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO - Google Patents

PROCESO PARA LA PURIFICACION DE PROTEINAS FARMACOLOGICAMENTE ACTIVAS A TRAVéS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO

Info

Publication number
CU23149A3
CU23149A3 CU112A CU20020112A CU23149A3 CU 23149 A3 CU23149 A3 CU 23149A3 CU 112 A CU112 A CU 112A CU 20020112 A CU20020112 A CU 20020112A CU 23149 A3 CU23149 A3 CU 23149A3
Authority
CU
Cuba
Prior art keywords
purification
pharmacologically active
proteins
cation exchange
exchange chromatography
Prior art date
Application number
CU112A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Lucia Scapol
Original Assignee
Alfa Waddermann S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Waddermann S P A filed Critical Alfa Waddermann S P A
Publication of CU23149A3 publication Critical patent/CU23149A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El objeto de la invencion es un proceso para la purificacion de proteínas farmacologicamente activas basado en el uso de cromatografía de intercambio cationico llevada a cabo en una matriz solida a un pH mAs bAsico, ej. superior, con respecto al pH correspondiente al punto isoelÉctrico pI, de las proteínas al ser purificadas, pH en el cual sin embargo dichas proteínas quedan todavía absorbidas. Las soluciones buffer con los valores de pH y de fuerza ionica ajustada de tiempo en tiempo al tipo de proteína farmacologicamente activa a ser purificadas son usadas para obtener tal resultado. El proceso estA principalmente dirigido a la purificacion del interferon y proteínas de albUmina.
CU112A 2001-07-06 2002-06-06 PROCESO PARA LA PURIFICACION DE PROTEINAS FARMACOLOGICAMENTE ACTIVAS A TRAVéS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO CU23149A3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001BO000426A ITBO20010426A1 (it) 2001-07-06 2001-07-06 Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico

Publications (1)

Publication Number Publication Date
CU23149A3 true CU23149A3 (es) 2006-06-29

Family

ID=11439471

Family Applications (1)

Application Number Title Priority Date Filing Date
CU112A CU23149A3 (es) 2001-07-06 2002-06-06 PROCESO PARA LA PURIFICACION DE PROTEINAS FARMACOLOGICAMENTE ACTIVAS A TRAVéS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO

Country Status (27)

Country Link
US (1) US6866782B2 (es)
EP (1) EP1273592B1 (es)
JP (1) JP3940037B2 (es)
KR (1) KR100771252B1 (es)
CN (1) CN100484954C (es)
AR (1) AR034663A1 (es)
AT (1) ATE307824T1 (es)
BG (1) BG65748B1 (es)
BR (1) BR0202431A (es)
CA (1) CA2388716C (es)
CU (1) CU23149A3 (es)
DE (1) DE60206847T2 (es)
DK (1) DK1273592T3 (es)
DZ (1) DZ3236A1 (es)
EG (1) EG23150A (es)
ES (1) ES2250544T3 (es)
HR (1) HRP20020480B1 (es)
HU (1) HUP0202124A2 (es)
IT (1) ITBO20010426A1 (es)
ME (1) MEP3408A (es)
MX (1) MXPA02006303A (es)
PL (1) PL209954B1 (es)
RS (1) RS51512B (es)
RU (1) RU2274471C2 (es)
SI (1) SI1273592T1 (es)
SK (1) SK287827B6 (es)
UY (1) UY27354A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1628729A2 (en) * 2003-05-16 2006-03-01 Cryobiophysica, Inc. External gradient chromatofocusing
WO2005100379A1 (ja) * 2004-03-30 2005-10-27 Hiroshi Yanagisawa タンパク質の分離方法
US7943046B2 (en) * 2004-10-01 2011-05-17 Agilent Technologies, Inc Methods and systems for on-column protein delipidation
US7449116B2 (en) * 2004-10-01 2008-11-11 Agilent Technologies, Inc. Methods and systems for protein separation
WO2008051178A2 (en) * 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US20100261275A1 (en) * 2007-12-10 2010-10-14 Yves Durocher Production of Recombinant Interferon Proteins
DE102009032179A1 (de) 2009-07-07 2011-01-13 Biogenerix Ag Verfahren zur Reinigung von Interferon beta
CN101768601B (zh) * 2010-02-01 2013-08-07 山东泉港药业有限公司 一种重组人血白蛋白—干扰素α2b的生产方法
JP6292718B2 (ja) * 2011-07-01 2018-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝集ポリペプチドから単量体ポリペプチドを分離するための方法
US8921113B2 (en) 2012-12-21 2014-12-30 Dionex Corporation Buffer kit and method of generating a linear pH gradient
CN118388581A (zh) 2013-03-08 2024-07-26 建新公司 治疗性蛋白药物物质的整合连续制造
CN104236983A (zh) * 2013-06-14 2014-12-24 中国科学院大连化学物理研究所 溶液样品中含长烷基链的离子液体的去除方法
TWI671312B (zh) 2014-01-17 2019-09-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
EP3221450A1 (en) * 2014-11-18 2017-09-27 Unichem Laboratories Limited An improved process for the preparation of pharmacopoeial grade interferon alpha 2b
CN106496302B (zh) * 2015-09-08 2021-12-10 三生国健药业（上海）股份有限公司 一种用离子交换层析纯化蛋白质的方法
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
BR112018011567A2 (pt) 2015-12-09 2018-11-27 Basf Se método de purificação de uma proteína de interesse, e, uso de um método.
GB2568936B (en) 2017-12-01 2019-12-25 Ford Global Tech Llc Liquid cooled injector
BR112021003420A2 (pt) 2018-08-31 2021-05-18 Genzyme Corporation resina cromatográfica estéril e uso da mesma em processos de manufatura
US11022585B2 (en) * 2019-06-09 2021-06-01 Dionex Corporation Methods and systems for optimizing buffer conditions with liquid chromatography
CN111138523A (zh) * 2019-12-10 2020-05-12 天津生机集团股份有限公司 一种从重组鸡干扰素α复性液中纯化制备重组鸡干扰素α的方法
CN113968900B (zh) * 2020-07-23 2023-07-25 中元汇吉生物技术股份有限公司 一种纯化C1q蛋白的方法
CN115918902A (zh) * 2022-12-19 2023-04-07 新疆农业科学院农业质量标准与检测技术研究所 一种通过微水波扩散重力法预处理葡萄脱水并获取高酚葡萄提取物的方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617401A1 (de) * 1966-05-02 1972-02-17 Centre Nat Rech Scient Verfahren zur Herstellung von Interferon-Praeparaten
US4228154A (en) * 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4534906A (en) * 1982-11-01 1985-08-13 Genentech, Inc. Removal of impurities from human leukocyte interferon preparations
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5250662A (en) * 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
US5440018A (en) * 1992-05-20 1995-08-08 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5521287A (en) * 1992-05-20 1996-05-28 The Green Cross Corporation Recombinant human serum albumin, process for producing the same and pharmaceutical preparation containing the same
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5367054A (en) * 1993-04-12 1994-11-22 Stolle Research & Development Corp. Large-scale purification of egg immunoglobulin
EP0679718B1 (en) * 1994-04-09 2001-09-05 F. Hoffmann-La Roche AG Process for producing alpha-interferon
JP3702474B2 (ja) * 1994-06-01 2005-10-05 三菱ウェルファーマ株式会社 血清アルブミン製剤の製造方法
RU2081122C1 (ru) * 1994-06-16 1997-06-10 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Способ выделения и очистки инсулина или его биотехнологических предшественников
US5486470A (en) * 1994-07-21 1996-01-23 Merck & Co., Inc. Purified herpes simplex virus protease and methods of purification
CA2157219C (en) 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
EP0871671A1 (en) * 1995-09-07 1998-10-21 PPL Therapeutics (Scotland) Limited Purification of alpha-1 proteinase inhibitor
RU2132386C1 (ru) * 1997-06-20 1999-06-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Способ получения рекомбинантного интерферона-гамма человека
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process

Also Published As

Publication number Publication date
YU50502A (sh) 2005-09-19
BG65748B1 (bg) 2009-09-30
RU2274471C2 (ru) 2006-04-20
MEP3408A (en) 2010-10-10
RU2002117383A (ru) 2004-01-27
PL354769A1 (en) 2003-01-13
HRP20020480B1 (en) 2006-11-30
SK8592002A3 (en) 2003-01-09
EP1273592A3 (en) 2003-03-19
HU0202124D0 (es) 2002-09-28
HUP0202124A2 (hu) 2003-10-28
CA2388716C (en) 2008-01-08
DE60206847D1 (de) 2005-12-01
MXPA02006303A (es) 2003-02-10
US6866782B2 (en) 2005-03-15
AR034663A1 (es) 2004-03-03
ITBO20010426A0 (it) 2001-07-06
US20030010715A1 (en) 2003-01-16
CN1396176A (zh) 2003-02-12
JP3940037B2 (ja) 2007-07-04
SI1273592T1 (sl) 2006-02-28
CA2388716A1 (en) 2003-01-06
BR0202431A (pt) 2003-09-09
PL209954B1 (pl) 2011-11-30
JP2003096092A (ja) 2003-04-03
DZ3236A1 (fr) 2005-04-20
KR100771252B1 (ko) 2007-10-30
ATE307824T1 (de) 2005-11-15
BG106768A (en) 2003-05-30
UY27354A1 (es) 2003-04-30
ES2250544T3 (es) 2006-04-16
EP1273592A2 (en) 2003-01-08
ITBO20010426A1 (it) 2003-01-06
SK287827B6 (sk) 2011-11-04
HRP20020480A2 (en) 2003-02-28
DE60206847T2 (de) 2006-07-06
DK1273592T3 (da) 2006-01-02
RS51512B (sr) 2011-06-30
EP1273592B1 (en) 2005-10-26
CN100484954C (zh) 2009-05-06
EG23150A (en) 2004-05-31
KR20030005005A (ko) 2003-01-15

Similar Documents

Publication Publication Date Title
AR034663A1 (es) Proceso para la purificacion de proteinas farmacologicamente activas mediante cromatografia de intercambio cationico
EA200100749A1 (ru) Синтетические пептиды, обладающие поверхностной активностью, и их применение для приготовления синтетического сурфактанта
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
PE20080339A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento
HUP0500042A2 (hu) HMG fragmensek alkalmazása gyulladásgátló szerként
TR200002179T2 (tr) Kristalin teriparatid.
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
PA8570001A1 (es) Aminoacidos con afinidad por la proteina a2 delta
TR200100056T2 (tr) Nörotrofik faktörler
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
ES2054601T3 (es) Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados.
ATE337017T1 (de) Positionelle isomeren von pegyliertem interferon alpha 2a
ES2033678T3 (es) Procedimiento para la preparacion de una proteina de fusion.
BR0312521A (pt) Métodos para a separação e a purificação de fibrinogênio e de pelo menos uma outra proteìna e para a co-purificação de fibrinogênio e de fator xiii, uso de cromatografia de afinidade com ìon de metal imobilizado, fibrinogênio, kit farmacêutico, e, formulações farmacêutica e de fibrinogênio liofilizado
UY37680A (es) Proteína de fusión con polipéptido de extensión de vida media
ES2070855T3 (es) Metodo para purificar una proteina.
ES2163418T3 (es) Inhibidores de una proteasa que es capaz de separar el receptor tnf soluble p55 del receptor tnf unido a la celula.
DK1098972T3 (da) Protein med lighed med neuroendokrinspecifikt protein samt cDNA kodende derfor
DK0710239T3 (da) Nye 9-N-bicycliske nucleosidmidler anvendelige som selektive inhibitorer af proinflammatoriske cytokiner
DK1363944T3 (da) Höjaffinitetsantagonister for ELR-CXC-kemokiner
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
DK1062244T3 (da) Forbedrede fremgangsmåder til fremstilling af faktor VIII proteiner

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)